ABSTRACT
Abacavir is a widely used nucleotide reverse transcriptase inhibitor, for which cerebrospinal fluid (CSF) exposure has been previously assessed in twice-daily recipients. We studied abacavir CSF concentrations in 61 and nine HIV-positive patients taking abacavir once daily and twice daily, respectively. Patients on once-daily abacavir had higher plasma and CSF concentrations (96 vs. 22 ng ml-1 , P = 0.038 and 123 vs. 49 ng ml-1 , P = 0.038) but similar CSF-to-plasma ratios (0.8 vs. 0.5, P = 0.500). CSF abacavir concentrations were adequate in patients receiving once-daily treatment.
Subject(s)
Anti-HIV Agents/administration & dosage , Anti-HIV Agents/cerebrospinal fluid , Dideoxynucleosides/administration & dosage , Dideoxynucleosides/cerebrospinal fluid , HIV Infections/drug therapy , Adult , Anti-HIV Agents/blood , Chromatography, High Pressure Liquid , Dideoxynucleosides/blood , Drug Administration Schedule , Drug Monitoring/methods , Female , HIV Infections/blood , HIV Infections/cerebrospinal fluid , HIV Infections/diagnosis , Humans , Italy , Male , Middle Aged , Tandem Mass Spectrometry , Time Factors , Treatment OutcomeABSTRACT
WHAT IS KNOWN AND OBJECTIVE: The second-generation direct-acting antivirals represented the first major turning point for the eradication of HCV infection in almost all settings of patients. However, no data were available on use in gastro-resected patients. CASE DESCRIPTION: We report on a gastrectomized patient with chronic hepatitis C infection. She was treated with sofosbuvir and ledipasvir (SOF/LDV) for 12 weeks, with measurement of blood levels of the drugs. She obtained sustained virological response at week 12 and 24 without dose adjustment. WHAT IS NEW AND CONCLUSION: This case report can provide information useful for clinical practice in this set of patients and can open new perspectives in evaluating actual SOF/LDV bioavailability.
